idea-017 · viability deck

Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.

Home NIV with tcCO2-Guided Titration — viability

The chair: the investor, and the operator who would have to run this as a Medicare DME (durable medical equipment) business — selling to DME suppliers who bill a capped monthly rental under a code that already exists, against two entrenched incumbents, under a coverage instrument CMS (Centers for Medicare & Medicaid Services) has already written.

How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-017.md with the claim's position in its ## Claims list and the tag it carries there, copied and never adjusted; a no-claim marker means nothing in the file speaks to the condition. No number appears here that isn't in a claim, and there is no ask slide. See docs/deck-spec.md.

What changed since the last build. The 2026-09-29 Verifier pass put the first dollar and volume figures on the file: the E0471 (a HCPCS code for durable medical equipment) descriptor is confirmed verbatim, the national Medicare E0471 rental volume is on record, and the July 2026 monthly allowable is published. Those figures sharpen the money question rather than close it. The code pays the same allowable whether or not the device carries a CO2 channel, and no HCPCS (Healthcare Common Procedure Coding System) code describes the sensor — so the question this deck now turns on is who pays for the channel. That condition had nothing behind it and is now claim 43unverified.

Slide 1 — Who pays, from which budget

Would have to be true: Medicare Part B (Medicare Part B)'s durable medical equipment benefit would have to pay for this, billed by a DME supplier as a monthly capped rental under HCPCS E0471 — which makes the manufacturer's customer the DME supplier, not the patient and not the prescribing practice.

Where it stands: The instrument, the code and the payment category are on the record; the code-to-NCD (national coverage determination) linkage is not. CMS established NCD 240.9 (a Medicare national coverage determination number) for home NIPPV in CRF consequent to COPD, effective 2025-06-09 claim 1verified, carried into the manual by Rev. 13808 with implementation 2025-10-22 claim 3verified. E0471's descriptor — "Respiratory assist device, bi-level pressure capability, with back-up rate feature, used with noninvasive interface" — is confirmed verbatim against the October 2026 HCPCS file claim 7verified. The July 2026 DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) fee schedule carries E0471 as category CR (capped rental) on an RR line only; the claim stays claim 8unconfirmed because the 2006 Federal Register rule it also names cannot be reached. The NCD names no HCPCS code, and its section D expressly preserves MAC (Medicare administrative contractor) discretion claim 4unconfirmed. The RAPID pathway is not a route here: it is limited to Breakthrough-designated devices claim 21verified, and the criterion immediately before the one the Generator cited reads "Not already the subject of a controlling Medicare NCD" claim 20verified — on the file's reading the candidate appears excluded, which the claim's note calls interpretation. That the DME supplier will stock and service a device with an extra consumable sensor is an assumption claim 28unconfirmed.

What would settle it: A human retrieval of the DME MAC (durable medical equipment Medicare administrative contractor) policy article A52517 to confirm E0471 is the code billed under the aligned LCD (local coverage determination), and a human fetch of the 2006 capped-rental rule (the policy connector rejects pre-2007 document numbers).

If it's false: If E0471 is not the code the aligned LCD pays for this population, the reimbursement factor loses its only paying instrument and every figure on Slides 2 and 3 is priced against the wrong code.

Slide 2 — The three reimbursement questions

Would have to be true: The code would have to exist with a descriptor this device fits; the allowable would have to be a number the business can be built on; and the coverage policy would have to permit what this device actually does — settings documented from a home overnight tcCO2 (transcutaneous carbon dioxide) recording — and pay for the sensor channel, not only the ventilator.

Where it stands:

Code exists: yes, with a descriptor for a bi-level device with back-up rate — the ventilator half only claim 7verified. No HCPCS Level II descriptor names a transcutaneous CO2 sensor or its consumables, and whether the sensor is bundled inside the E0471 rental is unread claim 34unconfirmed.
Payment amount: published — $324.35-$347.40 per rental month non-rural and $520.32-$579.71 rural, Medicare allowed amounts, varying by state claim 10unconfirmed. The tag holds back the per-patient arithmetic: 42 CFR 414.229 steps the monthly amount down after month 3 and caps payment at 13 months of continuous use, so one RR figure times 13 overstates even the ceiling.
Coverage policy: the NCD exists claim 1verified. Its high-intensity definition is IPAP ≥ 15 cm H2O with a back-up rate of at least 14, not IPAP above 20 as first claimed claim 5refuted — a looser envelope, not a tighter one. The NCD contains "transcutaneous" nowhere and specifies arterial PaCO2 throughout claim 30unconfirmed. LCD L33800 (a Medicare local coverage determination number) has never been read; the cache shows A52517 as its policy article, effective the same day as the NCD, with no prose claim 6unconfirmed.

What would settle it: A human read of LCD L33800 and article A52517 for the documentation requirement and for whether a sensor is included in the E0471 rental; the DME MAC's bundling rules. No connector reads LCD or article text by ID.

If it's false: If the sensor is neither separately payable nor recoverable inside the rental, the channel that differentiates the product is delivered at the manufacturer's or supplier's cost — see Slide 7. If L33800 requires arterial documentation, the recording channel is clinically optional and commercially invisible.

Slide 3 — TAM, decomposed

Would have to be true: Each factor of patients-on-therapy × months paid × monthly allowable would have to be a retrieved figure for this population — and the Medicare E0471 volume would have to be separable into the COPD-CRF share the device is indicated for.

Where it stands:

Population: ~16 million US adults with diagnosed COPD, with no primary table attached claim 12unconfirmed.
Rate / incidence: the share meeting NCD 240.9 criteria is an unsourced Generator estimate claim 11unconfirmed. The Medicare FFS (fee-for-service) floor that exists is code-level, not indication-level: 188,380 E0471 rental months across 32,920 beneficiaries in data year 2024 claim 9verified — a floor that excludes Medicare Advantage (Medicare Advantage), commercial, Medicaid, VA and cash-pay, and that counts every E0471 indication, not only COPD. Whether the COPD-CRF share of those beneficiaries can be read from a CMS source had nothing behind it before this build claim 44unverified.
Price: the monthly allowable is published, the per-patient total is not a single figure claim 10unconfirmed.
Reachable share and months paid: how many enrolled patients clear the NCD's continued-coverage adherence bar at 6 months and again at 7-12 months is unresearched; the utilization file's roughly 5.7 rental months per beneficiary is a one-year snapshot and is explicitly not a persistence rate claim 36unconfirmed.

No TAM (total addressable market) figure is computed here: three of the four factors are unconfirmed, and multiplying them would produce a number more precise than its inputs.

What would settle it: A CMS DME data source that breaks E0471 beneficiaries out by indication or diagnosis (a human has to find whether one exists); human-attached prevalence tables for COPD and hypercapnic CRF; a published persistence study for NCD-covered home NIV (non-invasive ventilation).

If it's false: TAM is one of the three gate-bearing factors, and a code-level floor that mostly counts other indications would be a floor under a different market.

Slide 4 — Capital to first dollar

Would have to be true: A two-subsystem product — a bi-level ventilator with back-up rate, a reusable heated tcCO2 sensor with a consumable element, and software that proposes settings — would have to reach 510(k) (premarket notification) clearance and a first billed E0471 rental without waiting on a new code, a new coverage decision, a De Novo (De Novo classification request) or a clinical study, at a cost and on a calendar that no claim in this file carries.

Where it stands: The no-new-code, no-new-coverage half is what Slides 1-2 establish (claims 1, 7). The regulatory half is unconfirmed: that FDA (US Food and Drug Administration) takes the combined device on a 510(k) without De Novo or a clinical study is a prediction about a decision not yet made claim 38unconfirmed; each half is cleared today under its own product code — MNS under 21 CFR (Title 21 of the Code of Federal Regulations) 868.5895 claim 18verified and LKD under 21 CFR 868.2480 claim 17verified — with no combined-function predicate found claim 19unconfirmed. Development cost and time to clearance: [no claim] — this blank is deliberate; no claim carries a budget or a calendar, and none is estimated here. The site-of-care saving the Generator framed against an attended titration study is weaker than first written: the NCD requires no attended titration, and the ATS guideline suggests against lab titration claim 14unconfirmed.

What would settle it: An FDA pre-submission on the combined device (a human act, and the only instrument that informs claim 38unconfirmed); an engineering cost-and-schedule estimate from people who have built a Class II (FDA device class II) ventilator, attached to the file as a claim with its source.

If it's false: If FDA reads the combination as a new device type, the program moves to De Novo with a clinical study and first revenue waits on it; the Capital-intensity factor has no verified input either way.

Slide 5 — What stops a fast-follower

Would have to be true: Something specific would have to stop ResMed or Philips Respironics from adding a tcCO2 recording channel to a bi-level platform they already have cleared — a patentable integration claim, an exclusive sensor supply, a data asset, or a coding advantage.

Where it stands: The only candidate mechanism in the file is a patent, and it is unexamined. That a patentable claim over the tcCO2-plus-titration-recommendation integration is available over ResMed, Philips and SenTec filings is claim 35unconfirmed; its note records leads only — a free-text scan matched nothing (which is not a clear field), a CPC A61M16 sweep returned 12 families none of which is titled as this integration, and the three named assignee portfolios were not swept. No supply lock, data asset or coding advantage is claimed anywhere; the coding position is the opposite of an advantage, since E0471 pays incumbents' devices identically (Slide 2). Both halves already exist in incumbents' hands: SenTec's cleared tcCO2 system and Philips' K102465 (an FDA 510(k) clearance number) are confirmed, ResMed's brand-to-clearance mapping is not claim 24unconfirmed.

What would settle it: ResMed-, Philips- and SenTec-assignee patent sweeps on the integration, then patent <id> on any close family, and a human patent attorney's read — patentability is a legal judgement, not a database fact.

If it's false: The Moat factor is empty, and the product is a feature an incumbent can ship as a line extension.

Slide 6 — Who is already there

Would have to be true: The incumbent field would have to leave an opening that is structural rather than a temporary dislocation — and an incumbent one line-extension away would have to have a reason not to take it.

Where it stands: The field is occupied on both halves claim 24unconfirmed, and the two product codes show no combined device, which is an absence-of-evidence result and not white space claim 19unconfirmed. The one dislocation on record is Philips: its 2021-06-14 recall covering ventilators, CPAP and bi-level devices is confirmed against six open openFDA records claim 22verified. The 2024 consent decree restricting its US sales is unread by anything in this repo, and whether its restrictions are still in force in September 2026 is unknown to the file claim 23unconfirmed.

What would settle it: A human read of the consent-decree docket or Philips' current investor filings for whether the sale restrictions still bind.

If it's false: If the decree has lifted, the only opening the Competitive-intensity row credited is gone, and this is a crowded field with no structural gap.

Slide 7 — The cheapest way to find out

Would have to be true: DME suppliers would have to pay more for an E0471 device with an integrated tcCO2 channel than for a standard E0471 device — even though Medicare pays both at the same capped-rental allowable, and no code pays for the sensor separately — or the channel's cost would have to be recovered somewhere else that is named.

Where it stands: Nothing in the file shows a supplier would pay a premium; the condition had nothing behind it before this build claim 43unverified. The two facts that make it the money question are both on record: the allowable is the same published number for any E0471 device claim 10unconfirmed, and no HCPCS code describes the sensor, with bundling inside the rental unread claim 34unconfirmed. The adjacent supplier assumption — that suppliers will stock, set up and service the extra sensor inside the allowable — is claim 28unconfirmed; its note records that the allowable is now known and supplier willingness is still unresearched.

What would settle it: Interviews with a handful of US DME suppliers who bill E0471 today: what they pay per unit now, whether a tcCO2 channel changes what they would pay, and what sensor service costs them per rental month. Cheap relative to anything on Slide 4; a human runs it.

If it's false: The differentiating channel is a cost with no revenue line, and the business reduces to selling a commodity E0471 device against incumbents at their price.

Slide 8 — Where this deck outruns the file

Every condition above with nothing verified behind it — the no-claim markers, plus the unverified claims this deck itself put on record. Read this slide first.

DME suppliers pay a premium for the tcCO2 channel under the same allowable — claim 43unverified — DME supplier interviews; a human runs them.
The COPD-CRF share of E0471 beneficiaries is readable from a CMS source — claim 44unverified — a human search of CMS DME data releases.
Development cost and time to 510(k) clearance — [no claim] — an engineering estimate from a Class II ventilator team, attached with its source.
The sensor is separately payable or bundled in the rental — claim 34unconfirmed — a human read of A52517 and the DME MAC bundling rules.
Revenue per enrolled patient over the capped rental — claim 10unconfirmed — the allowable is known; months paid depends on claim 36unconfirmed.
Patients sustain the continued-coverage adherence bar — claim 36unconfirmed — a published persistence study or primary research.
Suppliers stock and service the extra sensor inside the allowable — claim 28unconfirmed — supplier interviews.
FDA takes the combined device on a 510(k) without De Novo or clinical study — claim 38unconfirmed — a pre-submission.
A patentable integration claim exists — claim 35unconfirmed — assignee sweeps and an attorney's read.
The Philips consent-decree restrictions still bind — claim 23unconfirmed — a docket read.
LCD L33800 accepts home-recorded CO2 documentation — claim 6unconfirmed and claim 30unconfirmed — a human LCD retrieval.
E0471 is the code the NCD-aligned policy pays, with MAC discretion preserved — claim 4unconfirmed — the same A52517 read.
Population, rate and reachable share — claim 11unconfirmed and claim 12unconfirmed — human-attached prevalence tables.
The facility-side saving against an attended titration — claim 14unconfirmed — side (c) needs the MS-DRG cache; side (b) is weakened by the NCD and ATS text.

Fourteen of this deck's conditions rest on unverified, unconfirmed or [no claim]. Unlike the desirability deck, this one has real verified anchors (claims 1, 3, 7, 9, 17, 18, 20, 21,

— but every one of them establishes an instrument, a code, a volume floor or a clearance.

None of them says the channel this product adds is paid for.

Slide 9 — The load-bearing condition

If only one thing from this chair could be checked: whether DME suppliers will pay a higher unit price for an E0471 respiratory assist device with an integrated transcutaneous CO2 recording channel than for a standard E0471 device, even though Medicare pays both at the same E0471 capped-rental allowable claim 43unverified.

This one rather than the others because the file has now answered the questions that used to sit here — the code exists, the allowable is published — and the answers moved the risk onto this one. Every other money condition assumes the channel earns something; with no sensor code claim 34unconfirmed and one allowable for every E0471 device, this is the condition on which the product is a business rather than a feature, and it is checkable by a handful of supplier conversations.

Naming it is not a recommendation, a gate, or a kill.

Words on this page23 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md

21 CFR: Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k): premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
Class II: FDA device class II — moderate-risk devices, usually cleared by 510(k)
CMS: Centers for Medicare & Medicaid Services — the US agency that runs Medicare, and so decides what Medicare pays for
De Novo: De Novo classification request — the FDA route for a new, lower-risk device with no comparable product to point at; longer than a 510(k), usually needs clinical data
DME: durable medical equipment — equipment a patient uses at home, such as a pump or a stimulator, that Medicare pays for under its own rules
DME MAC: durable medical equipment Medicare administrative contractor — one of the four regional contractors that process Medicare's home-equipment claims and write its local coverage rules
DMEPOS: durable medical equipment, prosthetics, orthotics and supplies — the Medicare benefit and fee schedule that home equipment is paid under
E####: a HCPCS code for durable medical equipment — one billing code for a piece of home equipment; the letter E and four digits
FDA: US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
FFS: fee-for-service — the traditional form of Medicare that pays per item or service
HCPCS: Healthcare Common Procedure Coding System — the US billing codes for equipment, supplies and some services; a code is how a payer recognises what to pay for
K######: an FDA 510(k) clearance number — the public record of one cleared device; the letter K and six digits
L#####: a Medicare local coverage determination number — the public id of one local coverage rule; the letter L and five digits
LCD: local coverage determination — a Medicare contractor's rule, valid in its region, saying when something is covered
MAC: Medicare administrative contractor — a regional contractor that processes Medicare claims and writes local coverage rules
Medicare Advantage: Medicare Advantage — Medicare delivered through a private insurer; must cover at least what Medicare covers
Medicare Part B: Medicare Part B — the part of Medicare that pays for outpatient care and equipment used at home
NCD: national coverage determination — a Medicare rule, valid everywhere in the US, saying whether and when something is covered
NCD ###.#: a Medicare national coverage determination number — the public id of one national coverage rule
NIV: non-invasive ventilation — breathing support through a mask rather than a tube
TAM: total addressable market — how much money the whole market would be worth if every possible buyer bought
tcCO2: transcutaneous carbon dioxide — carbon dioxide measured through the skin, as a stand-in for a blood test

Generated from knowledge-base/decks/idea-017-viability.md by engine/scripts/build_review.py on 2026-10-04. This page is a view — edit the source file and rebuild, never edit here.